| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5845829 | Toxicology and Applied Pharmacology | 2016 | 8 Pages |
Abstract
The present study shows that treatment with the novel kinin B1 receptor antagonist, BI113823, reduces postinfarction cardiac remodeling and heart failure, and does not influence the cardiovascular effects of the ACE inhibitor.
Related Topics
Life Sciences
Environmental Science
Health, Toxicology and Mutagenesis
Authors
Xinchun Lin, Christian Bernloehr, Tobias Hildebrandt, Florian J. Stadler, Henri Doods, Dongmei Wu,